Skip to main navigation
logo
Careers
Contact Us
  • About Us
  • Technology
  • Pipeline
  • Products
    • DEXYCU
  • Investors
    • Financial Information
      • Financials Overview
      • Stock Information
      • Analyst Coverage
      • Ownership Summary
      • Annual Reports
      • Earnings Releases
      • SEC Filings
    • Resources
      • Press Releases
      • Events & Presentations
      • Publications
      • IR Contact
      • E-mail Alerts
    • Corporate Governance
      • Governance Overview
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • FAQs
    • Form 8937
  • News
Menu
  • About Us
  • Technology
  • Pipeline
  • Products
    • DEXYCU
  • Investors
    • Financial Information
      • Financials Overview
      • Stock Information
      • Analyst Coverage
      • Ownership Summary
      • Annual Reports
      • Earnings Releases
      • SEC Filings
    • Resources
      • Press Releases
      • Events & Presentations
      • Publications
      • IR Contact
      • E-mail Alerts
    • Corporate Governance
      • Governance Overview
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • FAQs
    • Form 8937
  • News
Menu
  • About Us
  • Technology
  • Pipeline
  • Products
    • DEXYCU
  • Investors
    • Financial Information
      • Financials Overview
      • Stock Information
      • Analyst Coverage
      • Ownership Summary
      • Annual Reports
      • Earnings Releases
      • SEC Filings
    • Resources
      • Press Releases
      • Events & Presentations
      • Publications
      • IR Contact
      • E-mail Alerts
    • Corporate Governance
      • Governance Overview
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • FAQs
    • Form 8937
  • News

Publications

  • Financial Information
    • Financials Overview
    • Stock Information
    • Analyst Coverage
    • Ownership Summary
    • Annual Reports
    • Earnings Releases
    • SEC Filings
  • Resources
    • Press Releases
    • Events & Presentations
    • Publications
    • IR Contact
    • E-mail Alerts
  • Corporate Governance
    • Governance Overview
    • Management Team
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • FAQs
  • Form 8937
A 12-Month, Ocular Pharmacokinetic Study of EYP-1901, a Sustained-release, Intravitreal Formulation of the Tyrosine Kinase Inhibitor Vorolanib
Subgroup Analyses of the Phase 1 DAVIO Trial of EYP 1901 Demonstrating Reduced Treatment Burden in Wet Age related Macular Degeneration
OIS Spotlight on Drug Delivery Presentation
The Neuroprotective Effect of Tyrosine Kinase Inhibitor Vorolanib in a Mouse Model of Retinal Detachment
The DAVIO Trial: A Phase 1, Open-Label, Dose-Escalation Study of a Single Injection of EYP-1901 (Vorolanib in Durasert® Platform) Demonstrating Reduced Treatment Burden in Wet Age-Related Macular Degeneration
12-Month Results of a Tyrosine Kinase Inhibitor (Vorolanib) in a Bioerodible Durasert® Insert for Previously Treated Neovascular AMD: The DAVIO Trial
8-month Results of a Tyrosine Kinase Inhibitor (Vorolanib) in a Bio-erodible Durasert® Implant for Previously Treated Wet AMD: The DAVIO Trial
Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
  • Print Page
  • Email Alerts
  • RSS News Feeds
  • Home
  • About
  • Technology
  • Products
  • Pipeline
  • Investors
  • Contact Us
  • News
  • Careers
  • Sitemap
  • Terms and Conditions
  • Privacy Policy
  • Patent Notification
Menu
  • Home
  • About
  • Technology
  • Products
  • Pipeline
  • Investors
  • Contact Us
  • News
  • Careers
  • Sitemap
  • Terms and Conditions
  • Privacy Policy
  • Patent Notification
EyePoint Logo

EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EYEPOINT, the EyePoint logo, DURASERT, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals.
© EyePoint Pharmaceuticals. All rights reserved.

09/2021
US-EYP-2100003

Linkedin
Facebook
Twitter